Pfizer’s Jonathan Emms becomes new ABPI president
pharmafile | April 11, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | ABPI, Deepak Khanna, Pfizer, jonathan emms
Jonathan Emms, UK managing director of Pfizer, has taken up his appointment as president of the ABPI, after his election to the post at the end of last year.
Jonathan takes over from Deepak Khanna, now the regional president of Europe oncology at MSD UK, and will serve for one year with the option of standing for re-election for a further year.
Looking ahead to his presidency, Emms said: “It is a great privilege to take on the role of presidency from Deepak and I want to thank him for his leadership over the past two years.
“Right now, our industry is facing many challenges. High barriers to getting innovative medicines to patients and low and slow usage across the NHS means we risk falling behind our European neighbours. As President, I want to tackle the challenges head on and work together – industry, Government and NHS – to make change happen.
“Above all else, and a priority for my presidency, is to ensure that we remain focused on patients – who stand at the heart of everything we do. I want to ensure that patients get the innovative medicines they need, when they need them, so they can enjoy the best possible health.”
Deepak Khanna, ABPI past president, says: “I have worked with Jonathan for the past two years and think very highly of him and I am extremely grateful for all his support.
“Jonathan has been very active on the board, was a key member of the negotiating team, and I am very confident he will serve the ABPI very well. I hand over my presidency with great optimism and excitement for the future, confident that industry will continue to flourish with a very strong industry association in place.”
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
